The Senate Special Committee on Aging was back at it this week discussing the woeful predicament of the domestic generic drug industry and its import-facing supply chain. This time, the Committee heard from four generic drug makers opposed to advocacy groups and Washington think tanks.
The Commerce Department should look to 7 C.F.R. Part 6 as a terrific example of how USDA has ensured that quota allocation benefits domestic manufacturers, not speculators.
